Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.
Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant ...
Chris Towers and I will be making the Offseason Tracker our home base for the next few weeks, churning out content as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback